| Adcetris (brentuximab vedotin) / Takeda, Pfizer |
| Completed | 2 | 102 | US, Canada, Europe | brentuximab vedotin, SGN-35, ADCETRIS | Seagen Inc., Millennium Pharmaceuticals, Inc. | Disease, Hodgkin | 08/10 | 05/15 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 2 | 58 | US, Canada, Europe | brentuximab vedotin, SGN-35, ADCETRIS | Seagen Inc., Millennium Pharmaceuticals, Inc. | Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | 08/10 | 06/16 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Completed | 2 | 110 | US, Europe | brentuximab vedotin, Adcetris | Seagen Inc., Millennium Pharmaceuticals, Inc. | Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin | 03/13 | 03/13 | | |
|
|
|
| Completed | 2 | 100 | Europe | Etoposide, Cyclophosphamide, Doxorubicin, Prednisone, Procarbazine, Dexamethasone, Dacarbazine, Brentuximab Vedotin | University of Cologne, Millennium Pharmaceuticals, Inc. | Hodgkin Lymphoma | 03/14 | 12/17 | | |
NCT01461538: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies |
|
|
| Completed | 2 | 84 | US | brentuximab vedotin, Adcetris; SGN-35 | Seagen Inc. | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors | 12/14 | 12/14 | | |
|
NCT01534078: Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma |
|
|
| Completed | 2 | 34 | US | Brentuximab Vedotin, Adcetris, SGN-35, SGN35, Adriamycin, vinblastine, and dacarbazine, Doxorubicin, Velban, DTIC | Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Seagen Inc. | Hodgkin Lymphoma | 01/15 | 01/18 | | |
|
NCT01396070: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level |
|
|
| Completed | 2 | 36 | US | Brentuximab vedotin, Adcetris, SGN-35 | Youn Kim, Seagen Inc. | Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome | 04/15 | 05/16 | | |
|
NCT01421667: A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma |
|
|
| Completed | 2 | 176 | US, Canada | brentuximab vedotin, Adcetris; SGN-35, rituximab | Seagen Inc. | Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell | 06/15 | 06/15 | | |
|
|
|
|
|
|
|
|
|
| Completed | 2 | 38 | Europe | Brentuximab Vedotin, Adcetris | University of Birmingham, Leukaemia Lymphoma Research, Millennium Pharmaceuticals, Inc. | Hodgkin Disease | 01/16 | 10/17 | | |
| Completed | 2 | 15 | Europe | Brentuximab Vedotin, SGN-35; Adcetris | Fondazione Italiana Linfomi ONLUS | Primary Mediastinal Large B Cell Lymphoma | 07/16 | 07/16 | | |
| Completed | 2 | 13 | Europe | BRENTUXIMAB VEDOTIN, SGN-35 | Fondazione Italiana Linfomi ONLUS | Relapsed/Refractory Hodgkin's Lymphoma | 07/16 | 10/17 | | |
| Completed | 2 | 57 | US | brentuximab vedotin, anti-CD30 ADC SGN-35, anti-CD30 antibody-drug conjugate SGN-35, antibody-drug conjugate SGN-35, SGN-35, Adcetris | City of Hope Medical Center, National Cancer Institute (NCI) | Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | 02/17 | 02/17 | | |
NCT01925612 / 2015-004741-54: Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Terminated | 2 | 87 | US, Europe, RoW | brentuximab vedotin, Adcetris, SGN-35, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin | Seagen Inc. | Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse | 05/17 | 05/17 | | |
|
|
|
|
|
NCT02623920: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Withdrawn | 2 | 0 | US | Brentuximab, Brentuximab Vedotin, Adcetris, Bendamustine, Treanda, Rituximab, Rituxan | University of Arizona | Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma | 05/17 | 05/17 | | |
NCT02594163 / 2015-001671-51: Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma |
|
|
| Terminated | 2 | 25 | US, Europe, RoW | Brentuximab Vedotin, Adcetris, Rituximab, Rituxan, Bendamustine, Treanda | Seagen Inc. | Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma | 09/17 | 09/17 | | |
|
BRAN, NCT02280785: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas |
|
|
| Completed | 2 | 33 | RoW | Brentuximab vedotin, Adcetris | Samsung Medical Center, Millennium Pharmaceuticals, Inc. | Non-Hodgkin Lymphoma | 12/17 | 09/18 | | |
NCT02408042: Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) |
|
|
| Withdrawn | 1/2 | 0 | US | Pembrolizumab, Etoposide, Ifosfamide, Mesna, Carboplatin, Brentuximab vedotin, Rituximab | Western Regional Medical Center | Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma | 11/15 | 11/15 | | |
NCT01874054: Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma |
|
|
| Completed | 1/2 | 55 | US | brentuximab vedotin, Adcetris; SGN-35, bendamustine | Seagen Inc. | Hodgkin Disease | 12/15 | 02/18 | | |
|
|
NCT01492088 / 2011-001240-29: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma |
|
|
| Completed | 1/2 | 36 | Europe, US, RoW | Brentuximab vedotin, SGN-35, ADCETRIS | Millennium Pharmaceuticals, Inc. | Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma | 10/16 | 04/18 | | |
|
| Completed | 1/2 | 67 | Europe | Brentuximab Vedotin, ADCETRIS, Etoposide, Soludomerin, Methylprednisolone, Cisplatin, Ara C, Cytarabine | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Millennium Pharmaceuticals, Inc. | CLASSICAL HODGKIN LYMPHOMA | 01/19 | 01/19 | | |
